Standard therapy for high grade glioma is a topic that is evolving, timely, and relevant. Guest Editors Isaac Yang, MD and Seunggu Han, MD have assembled a group of experts to highlight the latest updates on various forms of management of high grade glioma. Some of the articles included in this issue focus on Extent of Resection for Glioblastoma; Role of adjuvant radiation therapy; Survival benefit of the Temozolomide protocol; Alternative chemotherapeutic agents; The role of avastin; Radiology; Pseuodprogression and Treatment effect; Pathology; Medical Management; Management of insular gliomas; Use of motor mapping; GBM treatment with clinical trials for surgical resection; Clinical trials with immunotherapy; Clinical trials for small molecule inhibitors; Future role of CED for GBM treatment; Application of a vault nanoparticle therapy for GBM therapy; Management of high grade gliomas in pediatric populations; Targeting Glioma Stem Like Cells with a focus on CD 133; and Potential Role for STAT3 inhibitors in glioblastoma.

Standard therapy for high grade glioma is a topic that is evolving, timely, and relevant. Guest Editors Isaac Yang, MD and Seunggu Han, MD have assembled a group of experts on management of high grade glioma. Some of the articles in this issue include: Use of language mapping to aid resection of eloquent gliomas; Clinical trials with immunotherapy; Clinical trials for small molecule inhibitors; Nanotechnology potential applications for GBM therapy; High Grade Gliomas in children; Modern Advances in Brain Tumor Treatments; Molecular pathways of Avastin interactions for the treatment of glioblastoma; and Quality of Life and Outcomes in Glioblastoma management.

This issue of the Neurosurgery Clinics of North America, Guest Edited by Drs. Manish Aghi and Lewis Blevins, is devoted to Management of Pituitary Tumors. Experts in the field have assembled to provide articles on Imaging of the pituitary and parasellar region; Management of Incidentally Found Nonfunctional Pituitary Tumors; Endoscopic Surgery for Pituitary Tumors; Prolactinomas – Medical versus Surgical Management; Neurosurgery for Cushing’s Disease; Postoperative radiotherapy and stereotactic radiosurgery for pituitary tumors; Management options for persistent postoperative acromegaly; Medical management of persistent and recurrent Cushing’s disease; Management of Large Aggressive Nonfunctional Pituitary Tumors – Experimental Medical Options when Surgery and Radiation Fail; Pituitary Carcinoma; Visual Outcomes after Surgery For Nonfunctional Adenomas Causing Visual Compromise; and Hypopituitarism and Central Diabetes Insipidus: Peri-Operative Diagnosis and Management.

This issue of Neurosurgery Clinics, guest edited by Dr. Michael A. Vogelbaum, is devoted to Glioblastoma, Part I: Surgical Management and Adjuncts. This is one of four issues selected each year by the series Consulting Editors, Russell R. Lonser and Daniel K. Resnick. Articles in this issue include: Perioperative Management of Patients with Glioblastoma, Role of Resection in Glioblastoma Management, Advancing Imaging to Enhance Surgery, Intraoperative Imaging for High-Grade Glioma Surgery, Use of Intraoperative Fluorophores, Extent of Resection of Glioblastoma, Functional Mapping for Glioma Surgery: Preoperative Mapping Tools, Functional Mapping for Glioma Surgery: Intraoperative Mapping Tools, Surgical Adjuncts for Glioblastoma, Window of Opportunity Clinical Trials to Evaluate Novel Therapies for Brain Tumors, Stereotactic Laser Ablation of Glioblastoma, Radiosurgery for Glioblastoma, Challenges Associated with Reoperation in Patients with Glioma, and Surgery for Glioblastoma in Elderly Patients.

This book presents the latest research pertaining to the diagnosis, therapy and management of diffuse low-grade gliomas (DLGG) in adults, with a particular focus on the path towards individualised therapy for this kind of tumour. Recent research on the natural history of DLGGs and their interaction with the brain has led to new diagnostic and therapeutic strategies which increase survival and quality of life of the patient, and these methods are described in this book.

Treatment of patients with intracranial gliomas, especially high-grade neoplasms, usually requires postoperative adjuvant therapy. Significant progress in the understanding of tumor biology, technological advances in irradiation delivery, and development of novel antitumor drugs have led to an expansion of the therapeutic arsenal in neuro-oncology. This publication provides a unique review of the various options for adjuvant therapy. Special emphasis is on current evidence-based treatment standards and guidelines, and on perspectives of further improvement in long-term outcomes. Chapters review the histopathological and molecular features of gliomas and describe basic principles and clinical results of fractionated radiotherapy, stereotactic radiosurgery, brachytherapy, use of radiosensitizers, systemic chemotherapy and antiangiogenic therapy. Particular attention is paid to treatment of pediatric patients and to physical and psychological rehabilitation and supportive care at the end of life. This book and its accompanying volumes are mainly directed at neuro-oncologists, radiation oncologists, and other clinicians treating patients with brain tumors.

This book, now in its second edition, provides a comprehensive overview of current re-irradiation strategies, with detailed discussion of re-irradiation methods, technical aspects, the role of combined therapy with anticancer drugs and hyperthermia, and normal tissue tolerance. In addition, disease specific chapters document recent clinical results and future research directions. All chapters from the first edition have been revised and updated to take account of the latest developments and research findings, including those from prospective studies. Due attention is paid to the exciting developments in the fields of proton irradiation and frameless image-guided ablative radiotherapy. The book documents fully how refined combined modality approaches and significant technical advances in radiation treatment planning and delivery have facilitated the re-irradiation of previously exposed volumes, allowing both palliative and curative approaches to be pursued at various disease sites. Professionals involved in radiation treatment planning and multimodal oncology treatment will find it to be an invaluable aid in understanding the benefits and limitations of re-irradiation and in designing prospective trials.